Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. Methods: We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifestyle and demographic factors were collected at the time of the third dose, and immunogenicity analyses were carried out in a subgroup of patients at 4-6 weeks after the third dose. Results: BIs were experienced by 42% patients (82/194) with a median time since the last vaccination of 176 days. Older age (>50 years; aHR 0.38, 95% CI: 0.20-0.74), receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (aHR 0.52, 95%CI: 0.30-0.90) and having a titre of neutralising antibodies >20 (aHR 0.36, 95% CI: 0.12-1.07) were identified as protective factors. Conversely, anti-IL6R treatment and anti-CD20 therapy increased BI probability. BIs were mostly pauci-symptomatic, but the hospitalisation incidence was significantly higher than in HCWs (8.5% vs. 0.19%); the main risk factor was anti-CD20 therapy. Conclusions: Being older than 50 years and receiving csDMARDs were shown to be protective factors for BI, whereas anti-IL6R or anti-CD20 therapy increased the risk. Higher neutralising antibody titres were associated with a lower probability of BI. If confirmed in a larger population, the identification of a protective cut-off would allow a personalised risk-benefit therapeutic management of RA patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Vaccines - 11(2023), 11 vom: 02. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Picchianti-Diamanti, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Booster |
|---|
| Anmerkungen: |
Date Revised 27.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines11111684 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364972335 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364972335 | ||
| 003 | DE-627 | ||
| 005 | 20231226100705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines11111684 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM364972335 | ||
| 035 | |a (NLM)38006015 | ||
| 035 | |a (PII)1684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Picchianti-Diamanti, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. Methods: We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifestyle and demographic factors were collected at the time of the third dose, and immunogenicity analyses were carried out in a subgroup of patients at 4-6 weeks after the third dose. Results: BIs were experienced by 42% patients (82/194) with a median time since the last vaccination of 176 days. Older age (>50 years; aHR 0.38, 95% CI: 0.20-0.74), receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (aHR 0.52, 95%CI: 0.30-0.90) and having a titre of neutralising antibodies >20 (aHR 0.36, 95% CI: 0.12-1.07) were identified as protective factors. Conversely, anti-IL6R treatment and anti-CD20 therapy increased BI probability. BIs were mostly pauci-symptomatic, but the hospitalisation incidence was significantly higher than in HCWs (8.5% vs. 0.19%); the main risk factor was anti-CD20 therapy. Conclusions: Being older than 50 years and receiving csDMARDs were shown to be protective factors for BI, whereas anti-IL6R or anti-CD20 therapy increased the risk. Higher neutralising antibody titres were associated with a lower probability of BI. If confirmed in a larger population, the identification of a protective cut-off would allow a personalised risk-benefit therapeutic management of RA patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a booster | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a immunosuppressive therapy | |
| 650 | 4 | |a neutralising antibodies | |
| 650 | 4 | |a protective immunity | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Navarra, Assunta |e verfasserin |4 aut | |
| 700 | 1 | |a Aiello, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Laganà, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Cuzzi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Salmi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Vanini, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Maggi, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Meschi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Matusali, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Notari, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Agrati, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Salemi, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Di Rosa, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Passarini, Damiano |e verfasserin |4 aut | |
| 700 | 1 | |a Di Gioia, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Sesti, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Spinelli, Francesca Romana |e verfasserin |4 aut | |
| 700 | 1 | |a Corpolongo, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Chimenti, Maria Sole |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraioli, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Gian Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Benucci, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Li Gobbi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Anna Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Capri, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Puro, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 11(2023), 11 vom: 02. Nov. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:11 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines11111684 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 11 |b 02 |c 11 | ||